Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ATH-063
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $35.0 million
Deal Type : Series B Financing
Athos, an Autoimmune and Cancer Biotech, is Raising $35M for Clinical Trials
Details : Funds will support ATH-063, a small molecule therapeutic targeting inflammation and mucosal healing in Crohn’s Disease and Ulcerative Colitis.
Product Name : ATH-063
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 16, 2024
Lead Product(s) : ATH-063
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $35.0 million
Deal Type : Series B Financing
Lead Product(s) : ATH-063
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
Details : ATH-063 is a first-in-class, oral, small molecule, genomic regulator acts both by suppressing pro-inflammatory responses and inducing direct mucosal healing, being developed for inflammatory bowel diseases, other autoimmune diseases and solid cancers.
Product Name : ATH-063
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2023
Lead Product(s) : ATH-063
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATH-63
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Lahey Hospital & Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Athos to perform molecular analysis of biopsies from de-identified Inflammatory Bowel Disease patient having ATH-63, samples from Lahey Hospital & Medical Center based in Burlington, Massachusetts.
Product Name : ATH-63
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 07, 2022
Lead Product(s) : ATH-63
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Lahey Hospital & Medical Center
Deal Size : Undisclosed
Deal Type : Collaboration